The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Open accessAbstract
OBJECTIVE: While all second-generation antipsychotics (SGAs) are promoted for having a low risk of extrapyramidal side effects (EPS), clinical observations suggest differences between the various agents. Nevertheless, this question has never been examined in a systematic review and meta-analysis of head-to-head comparisons. METHODS: We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE (last search July 2009) for randomized, blinded studies comparing the following SGAs in the treatment of schizophrenia or related disorders: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, and zotepine. At least 3 reviewers extracted the data independently. The primary outcome was "use of antiparkinson medication." The results were combined in a meta-analysis. RESULTS: We included 54 studies with 116 arms. Risperidone was associated with more use of antiparkinson medication than clozapine, olanzapine, quetiapine, and ziprasidone. Ziprasidone showed more use of antiparkinson medication than olanzapine and quetiapine and zotepine more than clozapine. There was no significant difference between amisulpride and its comparators (olanzapine, risperidone, or ziprasidone). Quetiapine showed significantly less use of antiparkinson medication than the 3 other SGAs it was compared with (olanzapine, risperidone, and ziprasidone). Scale-derived data (Barnes Akathisia Scale and Simpson Angus Scale) were limited. CONCLUSIONS: Our meta-analysis demonstrates that there are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs. Even though the differences were relatively small, they might be important for individual patients and should be taken into account in drug choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 957
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
Self-citationCorrell, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Self-citationVelligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f53132 · Cited by 367
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Self-citationFalkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e328303e7a6 · Cited by 289
(2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 282
Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., Marcus, R., McQuade, R. D., Iwamoto, T., & Carson, W. H. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07061035 · Cited by 271
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Self-citationScherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243
Self-citationZiprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 240
Self-citationClozapine: guidelines for clinical management.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989) · PubMed · Cited by 226
Amisulpride versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Silveira da Mota Neto, J. I., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006624.pub2 · Cited by 205
Self-citationSubjective Response as a Predictor of Outcome in Pharmacotherapy: The Consumer Has a Point
Van Putten, T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280087009 · Cited by 188
Sertindole versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Schmid, F., Lewis, R., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006752.pub2 · Cited by 183
Self-citationThe 'atypicality' of antipsychotics: a concept re-examined and re-defined
Gründer, G., Hippius, H., & Carlsson, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2806 · Cited by 168
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 158
Self-citationAkathisia: An Updated Review Focusing on Second-Generation Antipsychotics
Kane, J. M., Fleischhacker, W., Hansen, L. K., Perlis, R. H., Pikalov, A., & Assunção-Talbott, S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04210 · Cited by 154
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Self-citationRisperidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schwarz, S., Schmid, F., Hunger, H., Kissling, W., & Leucht, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006626.pub2 · Cited by 121
Self-citationKarow, A., Czekalla, J., Dittmann, R., Schacht, A., Wagner, T., Lambert, M., SCHIMMELMANN, B. G., & Naber, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0110 · Cited by 116
Correll, C. U., & Kane, J. M. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0117 · Cited by 112
Clozapine: an atypical antipsychotic agent.
Ereshefsky, L., Watanabe, & Tk, T.-J. (1989) · PubMed · Cited by 102
Aripiprazole versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., El-Sayeh, H. G. G., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub3 · Cited by 91
Self-citationNovel antipsychotics, extrapyramidal side effects and tardive dyskinesia
Barnes, T. R. E., & McPhillips, M. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803003-00009 · Cited by 86
Tenback, D. E., van Harten, P. N., Slooff, C. J., van Os, J., & SOHO Study Group (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1438 · Cited by 86
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654 · Cited by 32
Self-citationGervin, M., Browne, S., Garavan, J., Roe, M., Larkin, C., & O’Callaghan, E. (1999) · European Psychiatry · doi:10.1016/s0924-9338(99)00228-x · Cited by 28
Classifying Antipsychotic Agents: Need for New Terminology
Jindal, R. D., & Keshavan, M. S. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00007 · Cited by 26
Zotepine versus other atypical antipsychotics for schizophrenia
Subramanian, S., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Kissling, W., Leucht, S., & Komossa, K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006628.pub3 · Cited by 15
Self-citationZotepine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006628.pub2 · Cited by 12
Self-citationAmisulpride versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Hunger, H., Schmidt, F., Schwarz, S., Neto, J. I. S. D. M., Kissling, W., & Leucht, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006624 · Cited by 4
Self-citation
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“A direct comparison between AP to calculate differences between the various AP was only presented by Rummel-Kluge, performing a head-to-head comparison [25] Leucht and colleagues [35] also showed that (i) all AP are associated with at least some weight gain compared with placebo and (ii) that olanzapine and clozapine…”
ResultSolmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Metadata
- Authors
- Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-31
- Volume
- 38
- Issue
- 1
- Pages
- 167-177
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2101228291
- Cited by
- 272
- References
- 45
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.